Tue.Nov 12, 2024

article thumbnail

Bayer's rising prostate cancer star Nubeqa crosses blockbuster barrier as Xarelto continues downward descent

Fierce Pharma

Despite generic headwinds to Xarelto and challenges across different sectors of the conglomerate suggesting “twists and turns” in the road ahead, Bayer is confident that the course it’s laid out th | As Xarelto generics continue to eat away at sales, Bayer's Nubeqa and Kerendia are picking up the slack while Regeneron-partnered Eylea makes for a solid base.

Sales 264
article thumbnail

Where Medicare Advantage Goes From Here

MedCity News

Now is the time for health plans to step up and embrace the tools and strategies that will not only meet regulatory demands, but also drive innovation in care delivery. The post Where Medicare Advantage Goes From Here appeared first on MedCity News.

113
113
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA rejects Intercept's ask for Ocaliva full nod in rare liver disease, but accelerated approval remains

Fierce Pharma

In the wake of an unfavorable advisory committee meeting in September, Intercept Pharmaceuticals’ bid to win full approval for its liver disease drug Ocaliva has come up short. | Intercept received a complete response letter from the FDA, dashing the company’s hopes of turning Ocaliva’s accelerated green light into a traditional approval for the rare autoimmune disease primary biliary cholangitis.

FDA 241
article thumbnail

Unlocking the Future of Radioligand Therapy: From Discovery to Delivering at Scale

MedCity News

As radiopharmaceuticals enter a new phase, industry leaders must rethink external services and internal capabilities to master the complexities of delivering advanced therapies. The post Unlocking the Future of Radioligand Therapy: From Discovery to Delivering at Scale appeared first on MedCity News.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

AstraZeneca CEO defends corporate oversight, $80B revenue target amid China probes

Fierce Pharma

Despite China’s investigations into insurance fraud, allegedly illegal importation of unapproved drugs and improper collection of patient data that have implicated senior executives, AstraZeneca CE | Despite China’s investigations that have implicated senior executives, AstraZeneca CEO Pascal Soriot argued that the company did not lose oversight and remains on track to achieve his ambitious $80 billion-by-2030 revenue goal.

Insurance 214
article thumbnail

Daiichi and AZ pull Dato-DXd filing with FDA and try again

pharmaphorum

Daiichi Sankyo and AstraZeneca give up on their NSCLC application for Dato-DXd, and refile seeking a narrower label

FDA 105

More Trending

article thumbnail

Merck drug for rare tumour hits phase 3 target

pharmaphorum

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) therapies after its drug candidate pimicotinib cleared a phase 3 trial.The German group said the CSF-1R inhibitor given as a once-daily, oral dose hit its primary endpoint in the MANEUVER study, achieving an objective response rate (ORR) at week 25 of 54% compared to 3.2% for a matched placebo in patients with TGCT, a rare disease affecting the joints and tendons.

Pharma 82
article thumbnail

With high hopes for the economy, AstraZeneca adds $2B to US investment in manufacturing, R&D

Fierce Pharma

Citing a rosy view of the U.S. | AstraZeneca on Tuesday revealed that it’s adding $2 billion more to its current outlay in the U.S., representing a total capital investment of $3.5 billion. The cash will be used to grow the company’s research and production footprint in the States by the end of 2026, generating more than 1,000 new jobs along the way.

article thumbnail

Neurogene Gene Therapy Shows Signs of Efficacy in Small Study, But an Adverse Event Spooks Investors

MedCity News

Neurogene’s Rett syndrome gene therapy has preliminary data supporting safety and efficacy of the one-time treatment. But a late-breaking report of a serious complication in a patient who received the high dose sent shares of the biotech downward. The post Neurogene Gene Therapy Shows Signs of Efficacy in Small Study, But an Adverse Event Spooks Investors appeared first on MedCity News.

Safety 84
article thumbnail

NHS England relaunches anti-smoking pill programme

pharmaphorum

'Game-changer' daily pill to quit smoking returns to NHS after three-year absence after a deal between Teva and NHS England

90
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

Fort Health Secures $5.5M to Expand Access to Integrated Pediatric Mental Health Care

MedCity News

Fort Health’s $5.5 million in funding was led by Twelve Below and Vanterra and included participation from Redesign Health, Blue Venture Fund and True Wealth Ventures. The post Fort Health Secures $5.5M to Expand Access to Integrated Pediatric Mental Health Care appeared first on MedCity News.

78
article thumbnail

Neurogene shares fall on Rett syndrome gene therapy data

pharmaphorum

Neurogene says Rett syndrome gene therapy improves clinical symptoms, but a serious adverse event causes shares to fall

94
article thumbnail

FDA clears Novavax to resume trials of Covid-19 and flu combo vaccine 

Pharmaceutical Technology

The FDA agreed for Novavax to continue trials of its vaccine combo after addressing a serious adverse event that paused trials.

FDA 90
article thumbnail

Next gen wearables: Transforming remote patient care

pharmaphorum

Virtual wards (also known as hospital at home) allow patients to get the care they need at home safely and conveniently, rather than being in hospital. The NHS is increasingly introducing virtual wards to support people at the place they call home, including care homes. In today’s podcast, web editor Nicole Raleigh speaks with Dr Samuel Ewing, global head of pharma partnerships at Doccla, about the next generation of digital tools such as wearable medical devices, as well as remote patient monit

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Understanding the FDA's Exemption for DSCSA Compliance

Pharmaceutical Commerce

In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.

FDA 59
article thumbnail

23andMe ends drug development and slashes staff

pharmaphorum

23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and sweeping job losses.The company that made its name by providing saliva-based genetic testing for health and ancestry to millions of people around the world made the decision as part of a major restructuring drive that will see 40% of its workforce lose their jobs.

59
article thumbnail

Why Blockchain is Key to Enhancing Supply Chain Integrity

Pharmaceutical Commerce

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jonathan Colehower, managing director, global operations & supply chain practice at UST, explains how the use of blockchain technology will become more prominent moving forward.

Pharma 59
article thumbnail

New $3.5b AstraZeneca investment to accelerate US R&D and manufacturing

European Pharmaceutical Review

To boost AstraZeneca’s research and manufacturing footprint by the end of 2026, it is dedicating $3.5 billion of capital investment in the US. Of this amount, $2 billion will generate over 1,000 new jobs, the company added. AstraZeneca highlighted its US footprint is expanding in multiple areas such as: • a state-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts • next generation biologics manufacturing facility based in Maryland • cell therapy manufacturing capacity on the W

article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A

article thumbnail

Chasing $80bn sales target, AZ unveils $3.5bn US investment

pharmaphorum

AstraZeneca plans to invest a whopping $3.5 billion to expand its R&D and manufacturing operations in the US by 2026 as part of a drive to raise its revenues to $80 billion by the end of the decade.The programme – part of the pharma group's Ambition 2030 effort – will include the construction of a new R&D centre at Kendall Square in the heart of the biopharma hub in Cambridge, Massachusetts, and a biologics manufacturing facility in Maryland.

article thumbnail

Uppsala and KTH Royal develop antibody for potential cancer treatment

Pharmaceutical Technology

A team of researchers from Uppsala University and KTH Royal Institute of Technology in Sweden has developed a new antibody, which could potentially treat various types of cancer.

52
article thumbnail

Empowering Chief Medical Officers: Key Insights at the 2025 Healthcare CMO Summit

PM360

The 2025 Healthcare CMO Summit is an exclusive invitation-only event designed to bring together Chief Medical Officers (CMOs) and innovative suppliers and solution providers. Scheduled for February 3-4, 2025 , at The Ritz-Carlton Dallas, Las Colinas , the summit will address key clinical healthcare challenges and relevant market developments. Key Topics The summit will cover a range of critical topics, including: Reviving the Hospital Workforce: Addressing staffing shortages and productivity de

Medical 52
article thumbnail

Risk-Based Development Supporting Process Qualification for Spray-Dried Dispersion

PharmaTech

Spray drying enables the production of amorphous solid dispersions, allowing efficient scale-up from small screening batches to commercial levels. By leveraging small-scale experiments for process design and qualification, a robust validation strategy can be developed to support flexible, scalable manufacturing for small-molecule drug products.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Healthcare CNO Summit 2025: Uniting Leaders in Nursing for Innovation and Collaboration

PM360

The 2025 Healthcare CNO Summit , an exclusive invitation-only event, is scheduled for February 3-4, 2025, at The Ritz-Carlton Dallas, Las Colinas. This premier summit aims to bring together influential Chief Nursing Officers (CNOs) and innovative suppliers to address the evolving challenges in healthcare and foster strategic partnerships. The summit will focus on critical topics essential to the nursing profession, including: CNE Leadership Role: Examining the essential skill set that impacts n

article thumbnail

How to Boost Your Optical Business Sales in Malaysia

Contrarian Sales Techniques

Having worked with numerous optical businesses across Malaysia, from bustling Klang Valley to growing cities like Penang and Johor Bahru, I understand the unique challenges of our local market. Let me share proven strategies that have helped Malaysian opticians transform their businesses into thriving enterprises. Understanding the Malaysian Optical Market Landscape The Malaysian optical market is uniquely diverse, serving customers from various cultural backgrounds and income levels.

Sales 52
article thumbnail

Innovations & Challenges in Brain Health

PM360

Brain health is a notoriously difficult domain of medicine. What recent advancements excite you, and how can we foster continued innovation in this area? Brain health is undoubtedly one of the most challenging areas of medicine, often called the “last frontier.” The brain shapes who we are and how we see the world, yet treating brain health disorders is a monumental challenge.

article thumbnail

FDA Approves Autolus’ Aucatzyl for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

PharmExec

Approval of Aucatzyl was based on results of the FELIX trial, which demonstrated a 63% overall complete remission rate among efficacy-evaluable patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

FDA 52
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

The Women’s Edge and The Boston Globe Again Name CCC to Top 100 Women-Led Businesses in Massachusetts List

Copyright Clearance Center

November 12, 2024 – Danvers, Mass. – The Women’s Edge and its partner, The Boston Globe , announced that CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, was named to its annual Top 100 Women-Led Businesses in Massachusetts list. CCC ranked #16. This is the 24 th year that The Women’s Edge, a Boston-based nonprofit organization devoted to advancing women in leadership positions, has created the list through a nomination process and reviewed both for-p

article thumbnail

AstraZeneca, Daiichi Sankyo Submit Biologics License Application of Datopotamab Deruxtecan for Advanced Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer

PharmExec

Decision to submit the Biologics License Application of datopotamab deruxtecan was based on feedback from a previously withdrawn application to the FDA for nonsquamous non-small cell lung cancer.

FDA 52
article thumbnail

Zai Lab and argenx announce NMPA approval for sBLA for VYVGART Hytrulo

Pharmaceutical Technology

Zai Lab and argenx have announced receipt of approval from the National Medical Products Administration (NMPA) of China for the supplemental biologics license application (sBLA) for VYVGART Hytrulo 1,000mg vial for treating chronic inflammatory demyelinating polyneuropathy (CIDP) in adults.

Medical 52
article thumbnail

Pharma Pulse 11/12/24: Takeaways From Midlife MS Patients, The Power of Simplicity for First-in-Human Studies & more

PharmExec

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Pharma 52
article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud